we are

Inmunova is an Argentine biotechnological company dedicated to research and development of innovative medicines for rare infectious diseases with few or no treatment options.
We are part of Grupo Insud, a diversified global company with important worldwide presence in the pharmaceutical industry and operations in more than 40 countries.
We are specialized in the design of vaccines, therapeutic antibodies and immunogens, covering the entire development process: the original idea, the proofs of concept, the pre-clinical and clinical research phases, the registration procedure and the pharmacovigilance.
We have developed an innovative drug candidate with the potential to be the first treatment in the world to prevent the hemolytic uremic syndrome (HUS), currently in clinical research.
During the pandemic we developed an anti-SARS-CoV-2 polyclonal hyperimmune serum to treat moderate to severe COVID-19 disease, approved by Argentina's Health Authority (ANMAT) at the end of 2020, CoviFab®, which was used in more than 25,000 patients.
We are committed to the highest global quality standards and good practices for the research and development of our assets.



Inmunova is a biotechnological company founded in 2009 by scientists from Fundación Instituto Leloir, one of the most outstanding research centers in Latin America, with the vision of providing responses to diseases with high medical needs.

Since then, we have consolidated ourselves as a model of public-private articulation, developing research projects with universities and public and private partners. Today we are part of Grupo Insud. 

Different technologies that we have developed with the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) are protected by patents in Argentina and in more than 15 countries.

As of 2016 our headquarters are located at Fundación Argentina de Nanotecnología (FAN).

Innovation and scientific quality are the bases of our work, recognized by Fundación Endeavor to be part of an international network of innovative companies. Furthermore, Inmunova was awarded with the Gran Innova Award 2017 granted by Samsung and with the Visa-La Nación Innovation Award 2021, in the category Technology at the Service of Community, “for being pioneers in improving and adapting technology to offer new products and/or services during COVID-19 pandemic”.



At Inmunova we share values that guide our work and the achievement of our goals.

Integrity and




Respect and equal


Management team

Linus Spatz

Founding Partner and General Director

Linus Spatz is Founding Partner and General Director of Inmunova. Biologist graduated from Universidad de Buenos Aires (UBA) he worked for many years in research and teaching at the Microbiology Department at the UBA’s School of Medicine. After being awarded with the NAVES Prize in 2001 (granted by IAE Business School, Universidad Austral) Linus became an entrepreneur in the Biotechnology field. He was Commercial Director of BioExt S.A., worked in various developments at Biotay S.A. and he was an advisor of CITES’ Board of Directors –CITES is the incubator of scientific and technological startups of Grupo Sancor Seguros–. He studied Business Management at IAE, Finance at Universidad Torcuato Di Tella (Argentina), and Management at Stanford University (USA). Linus is part of the international entrepreneur network of Fundación Endeavor and he collaborates by assisting Biotechnology ventures.

Fernando Goldbaum

Founding Partner and Scientific Director

Fernando Goldbaum is Founding Partner and Scientific Director of Inmunova. PhD in Biochemistry from the School of Pharmacy and Biochemistry of the Universidad de Buenos Aires, he carried out his post-doctoral training at the Center for Advanced Research in Biotechnology of the University of Maryland (USA), with specialization in structural immunology and antibody engineering. He is also Superior Researcher at the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Director of the Centro de Rediseño e Ingeniería de Proteínas (CRIP, Universidad de San Martin) and Director of the Immunology and Molecular Microbiology Laboratory at Fundación Instituto Leloir. Previously, he was Director of the Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA) and the Fundación Instituto Leloir. Dr. Fernando Goldbaum was awarded with AMSUD-Pasteur BIOTECH Prize 2004 for the development of a new technology for vaccine design; Heberto Castillo Martínez Prize 2012 in the Latin American Scientific category, from the Instituto de Ciencia y Tecnología (Mexico DF); Konex Award 2013 in Biotechnology; Jorge Sábato Award 2018 from the Secretaría de Ciencia, Tecnología e Innovación Productiva de la Nación (Argentina). He has published 136 scientific works in peer reviewed journals and is author of several biotechnological patents.

Vanesa Zylberman

Technical Director

Vanesa Zylberman is Technical Director of Inmunova. Besides, she is also an Independent Researcher at the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Biologist and PhD in Biological Sciences from the School of Exact and Natural Sciences of the Universidad de Buenos Aires (UBA), she did her doctorate at the Immunology and Molecular Microbiology laboratory, directed by Dr. Fernando Goldbaum, at Fundación Instituto Leloir. She has an important career in the development of innovative biotechnological products for human and animal health, such as vaccines and immunogens. Vanesa is author and co-author of more than 25 scientific papers and several biotechnological patents.

Santiago Sanguineti

Business Development Director

Santiago Sanguineti is Business Development Director of Inmunova. He holds a PhD in Biological Chemistry with specialization in protein Biochemistry from the Universidad de Buenos Aires (UBA). After finishing his doctoral studies, Santiago was awarded with the prestigious Chevening Scholarship granted by the Foreign Commonwealth Office to attend a Master in Business at the University College of London and the London Business School (UK). When he returned to Argentina, he started his career in the technology transfer area. He was Senior Consultant at the Technology Transfer Office of the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and General Manager of INIS-Biotech S.A./ Fundación Instituto Leloir.

Mariana Colonna

Responsible of Clinical Research and Regulatory Affairs

Mariana Colonna is Responsible of Clinical Research and Regulatory Affairs of Inmunova. Biochemistry from the Universidad de Buenos Aires (UBA), with postgraduate residency in Biochemistry, Clinical Biochemistry and Microbiology conducted at the Hospital General de Agudos "Dr. Juan A. Fernández". Mariana has wide experience in clinical research initiated at Quintiles, then at Schering-Plough Research Institute and later on at MSD laboratory, where she was Manager of Clinical Research Projects in charge of managing multicenter Phase I-IV studies. She was a Consultant (rank 4 Coordinator) at Fundación Instituto Leloir for the "Translational Medicine Program for innovations in research, diagnosis and treatment of Alzheimer's disease", of the Translational Research Biotechnological Projects Program of the Agencia Nacional de Promoción Científica y Tecnológica (ANPCYT). Nowadays she also serves as Research Advisor at Fundación Mundo Sano.

Erica Meneghel

Responsible of Quality Management

Erica Meneghel is Responsible of Quality Management of Inmunova. Biochemistry from Universidad de Morón, she has 20 years’ experience in the management of quality control systems, Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP) in the pharmaceutical industry. She was Supervisor of Quality Control and Microbiology at Therabel Pharma S.A./ Pharmatrix S.A. and Supervisor of Documentation and Quality Control Standards at Fada Pharma S.A. Later on, and during more than five years, she was Head of Quality Control of two production plants of Laboratorio Internacional Argentino S.A. Before joining Inmunova, Erica worked as a Consultant in her area of expertise for companies in the pharmaceutical, cosmetic and medical technology industries.